178
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?

ORCID Icon & ORCID Icon
Pages 2283-2285 | Received 13 Aug 2020, Accepted 13 Aug 2020, Published online: 08 Sep 2020
 

Disclosure statement

Dr. Tam reports grants and personal fees from Janssen, grants and personal fees from Abbvie, grants and personal fees from Beigene, during the conduct of the study.

Additional information

Funding

For author S. H. Handunnetti: Honoraria from Gilead & Roche; travel expenses from AbbVie; non-financial assistance from Novartis.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.